Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.59, $0.06 worse than the analyst estimate of $0.65. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $4.03 billion.

GUIDANCE:

Teva Pharma reaffirms FY2021 EPS of $2.50-$2.70 and revenue of $16-16.4 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.